country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-109047

Copy Link Print Information

Adafosbuvir

(Synonyms: AL-335)

Adafosbuvir (AL-335), a precursor compound of a uridine-based nucleotide analog polymerase (NS5B) inhibitor, has potent antiviral activity against HCV and acts as a potent inhibitor of HCV RNA polymerase.

For research use only. We do not sell to patients.

CAS No.: 1613589-09-5
Formula: C₂₂H₂₉FN₃O₁₀P
Molecular Weight:545.45

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (269 KB)

Adafosbuvir Chemical Structure

CAS No.: 1613589-09-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- Clinical Trial
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

RNA Polymerase

All DNA/RNA Synthesis Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	CC₅₀	>100 μM Compound: 53; AL-335	Cytotoxicity against human A549 cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay Cytotoxicity against human A549 cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay	[PMID: 30951311]
HeLa	CC₅₀	>100 μM Compound: 53; AL-335	Cytotoxicity against human HeLa cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay Cytotoxicity against human HeLa cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay	[PMID: 30951311]
HepG2	CC₅₀	>50 μM Compound: 35	Cytotoxicity against human HepG2 cells after 96 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells after 96 hrs by CCK-8 assay	[PMID: 29801997]
HepG2	CC₅₀	>100 μM Compound: 53; AL-335	Cytotoxicity against human HepG2 cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay Cytotoxicity against human HepG2 cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay	[PMID: 30951311]
Huh-7	CC₅₀	96.1 μM Compound: 53; AL-335	Cytotoxicity against human HuH7 cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay Cytotoxicity against human HuH7 cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay	[PMID: 30951311]
MT4	CC₅₀	>100 μM Compound: 53; AL-335	Cytotoxicity against human MT4 cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay Cytotoxicity against human MT4 cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay	[PMID: 30951311]
U-937	CC₅₀	>100 μM Compound: 53; AL-335	Cytotoxicity against human U937 cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay Cytotoxicity against human U937 cells treated for 8 days measured post-last dose by Celltiter-glo luminescent assay	[PMID: 30951311]

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1613589-09-5
Molecular Weight 545.45
Formula C₂₂H₂₉FN₃O₁₀P
SMILES

C[C@@]1([C@H](N(C=CC2=O)C(N2)=O)O[C@@](COP(OC3=CC=CC=C3)(N[C@@H](C)C(OC(C)C)=O)=O)(F)[C@H]1O)O
Synonyms

AL-335
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (269 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Tetsuo Takehara, et al. JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study. J Gastroenterol. 2020 Jun;55(6):640-652. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Get Quote In-stock